BACKGROUND: Several metabolic derangements associated with diabetes mellitus type 2 (DM) have been associated with a better outcome in amyotrophic lateral sclerosis (ALS), including hyperlipidemia and obesity. Here, we tested the hypothesis that DM would have a positive effect on the motor and cognitive findings of ALS. METHODS: We compared data from ALS patients with pre-morbid DM (ALS-DM; n = 175) versus without DM (ALS; n = 2196) with regard to the age of onset, rate of motor progression, survival, and neuropsychological test performance. RESULTS: The age of onset was later for women, Caucasians and patients with bulbar-onset ALS. However, we also found that after adjusting for gender, ethnicity and site of onset, DM was associated with a 4-year later onset of ALS (ALS = 56.3, ALS-DM = 60.3, P < 0.05). CONCLUSION: Diabetes mellitus type 2 may delay the onset of motor symptoms in ALS. These findings support other studies suggesting a relationship between the pathophysiology of ALS and metabolic derangements. Further investigations are needed to ascertain whether manipulating metabolic parameters would improve outcomes in ALS.
BACKGROUND: Several metabolic derangements associated with diabetes mellitus type 2 (DM) have been associated with a better outcome in amyotrophic lateral sclerosis (ALS), including hyperlipidemia and obesity. Here, we tested the hypothesis that DM would have a positive effect on the motor and cognitive findings of ALS. METHODS: We compared data from ALSpatients with pre-morbid DM (ALS-DM; n = 175) versus without DM (ALS; n = 2196) with regard to the age of onset, rate of motor progression, survival, and neuropsychological test performance. RESULTS: The age of onset was later for women, Caucasians and patients with bulbar-onset ALS. However, we also found that after adjusting for gender, ethnicity and site of onset, DM was associated with a 4-year later onset of ALS (ALS = 56.3, ALS-DM = 60.3, P < 0.05). CONCLUSION:Diabetes mellitus type 2 may delay the onset of motor symptoms in ALS. These findings support other studies suggesting a relationship between the pathophysiology of ALS and metabolic derangements. Further investigations are needed to ascertain whether manipulating metabolic parameters would improve outcomes in ALS.
Authors: Cassie S Mitchell; Sabrina K Hollinger; Shivani D Goswami; Meraida A Polak; Robert H Lee; Jonathan D Glass Journal: Neurodegener Dis Date: 2015-02-20 Impact factor: 2.977
Authors: R M Ahmed; E Mioshi; J Caga; M Shibata; M Zoing; L Bartley; O Piguet; J R Hodges; M C Kiernan Journal: J Neurol Date: 2014-06-24 Impact factor: 4.849
Authors: Rebekah M Ahmed; Yazi D Ke; Steve Vucic; Lars M Ittner; William Seeley; John R Hodges; Olivier Piguet; Glenda Halliday; Matthew C Kiernan Journal: Nat Rev Neurol Date: 2018-03-23 Impact factor: 42.937
Authors: R M Ahmed; J Caga; E Devenney; S Hsieh; L Bartley; E Highton-Williamson; E Ramsey; M Zoing; G M Halliday; O Piguet; J R Hodges; M C Kiernan Journal: J Neurol Date: 2016-06-03 Impact factor: 4.849
Authors: Maria A Lim; Kendra K Bence; Ishani Sandesara; Pénélope Andreux; Johan Auwerx; Jeff Ishibashi; Patrick Seale; Robert G Kalb Journal: Hum Mol Genet Date: 2014-05-15 Impact factor: 6.150